Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer

Epidermal growth factor receptor (EGFR) is overexpressed in >60% of non-small cell lung cancer (NSCLC) cases. In combination with radiotherapy or chemotherapy, first-line treatments with antibodies against EGFR, including cetuximab and necitumumab, have demonstrated benefits by increasing overall...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2017-02, Vol.13 (2), p.912-920
Main Authors: Avilés-Salas, Alejandro, Muñiz-Hernández, Saé, Maldonado-Martínez, Héctor Aquiles, Chanona-Vilchis, José G, Ramírez-Tirado, Laura-Alejandra, HernáNdez-Pedro, Norma, Dorantes-Heredia, Rita, RuíZ-Morales, José Manuel, Motola-Kuba, Daniel, Arrieta, Oscar
Format: Article
Language:English
Subjects:
Asbestos
Cancer therapies
Care and treatment
Chemotherapy
Development and progression
Epidermal growth factor
Females
Genetic aspects
Immunohistochemistry
Immunotherapy
Lung cancer
Lung cancer, Non-small cell
Methods
Monoclonal antibodies
Mortality
Multivariate analysis
Oncology
Reproducibility
Smoking
Targeted cancer therapy
Tobacco
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epidermal growth factor receptor (EGFR) is overexpressed in >60% of non-small cell lung cancer (NSCLC) cases. In combination with radiotherapy or chemotherapy, first-line treatments with antibodies against EGFR, including cetuximab and necitumumab, have demonstrated benefits by increasing overall survival (OS), particularly in patients who overexpress EGFR. The present study evaluated the interobserver agreement among three senior pathologists, who were blinded to the clinical outcomes and assessed tumor samples from 85 patients with NSCLC using the H-score method. EGFR immunohistochemistry was performed using a qualitative immunohistochemical kit. The reported (mean ± standard deviation) H-scores from each pathologist were 111±102, 127±103 and 128.53±104.03. The patients with average H-scores ≥1, ≥100, ≥200 and between 250-300 were 85.9, 54.1, 28.2 and 12.9, respectively. Patients who had an average H-score >100 had a shorter OS time compared with those with lower scores. Furthermore, patients with EGFR mutations who were treated with EGFR-tyrosine kinase inhibitors (TKIs) and had an average H-score >100 had a longer OS time compared with those with an average H-score
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2016.5512